How Is Dupixent Administered?

What Kind of Injection Is Dupixent?

Dupixent is a subcutaneous (under-the-skin) injection. It is not an intravenous infusion and it is not an intramuscular shot. The drug is a human monoclonal antibody targeting the IL-4 receptor alpha subunit, which blocks both IL-4 and IL-13 signaling. Because of its molecular size, subcutaneous delivery allows slow systemic absorption with a half-life of roughly 21 days, which supports a biweekly or monthly schedule. The FDA prescribing information confirms subcutaneous administration as the only approved route. [1]

Pre-Filled Syringe vs. Pre-Filled Pen

Dupixent is packaged in two device formats:

• Pre-filled syringe (300 mg/2 mL): A traditional syringe with a fixed needle. Gives the injector more tactile control and is often preferred for caregivers administering to children.
• Pre-filled pen (autoinjector, 300 mg/2 mL): A spring-loaded device that hides the needle. Many adult patients prefer the pen for self-injection because it does not require the user to see the needle.

Both devices deliver the same 300 mg dose per unit. A 600 mg loading dose requires two sequential injections at two different sites.

Why Subcutaneous and Not Oral?

Dupilumab is a 146-kilodalton IgG4 monoclonal antibody. Oral delivery would destroy it through gastrointestinal proteolysis before systemic absorption could occur. Subcutaneous tissue provides a depot from which the antibody enters the lymphatics and then the bloodstream gradually, producing stable serum concentrations after four to six weeks of biweekly dosing. Pharmacokinetic data published in the Journal of Clinical Pharmacology confirm steady-state is reached by week 16 in most adult patients. [2]

Dupixent Dosing Schedule by Indication

The dose and interval vary by approved indication and by patient age or weight band. The table below reflects the FDA-approved prescribing information as of the 2023 label update. [1]

Atopic Dermatitis (Adults and Adolescents 12 Years and Older)

Adults (18+) and adolescents 12 to 17 years weighing 60 kg or more receive:

• Loading dose: 600 mg subcutaneously (two 300 mg injections at different sites on the same day)
• Maintenance: 300 mg every other week

Adolescents 12 to 17 years weighing less than 60 kg receive:

• Loading dose: 400 mg (two 200 mg injections)
• Maintenance: 200 mg every other week

The SOLO-1 and SOLO-2 trials (combined N=1,379 adults) showed that 300 mg every-other-week dosing produced an IGA 0/1 (clear or almost clear skin) response in 36% to 38% of patients at week 16, compared with 8% to 9% for placebo (P<0.001). These results were published in the New England Journal of Medicine in 2016. [3]

Atopic Dermatitis in Children Ages 6 Months to 11 Years

Dosing for younger children is weight-based per the 2023 FDA label update [1]:

| Weight band | Dose | Frequency | |---|---|---| | 5 kg to <15 kg | 200 mg | Every 4 weeks | | 15 kg to <30 kg | 300 mg | Every 4 weeks | | 30 kg to <60 kg | 400 mg | Every 4 weeks | | 60 kg and above | 600 mg loading, then 300 mg | Every 2 weeks |

No loading dose is used for children under 12. The LIBERTY AD PEDS trial (N=251, ages 6 months to 5 years) demonstrated that the weight-based every-4-week schedule achieved IGA 0/1 in 28% of patients vs. 4% placebo at week 16. [4]

Moderate-to-Severe Asthma (Adults and Children 6 Years and Older)

Adults and adolescents 12+ receive 200 mg or 300 mg every other week, depending on the presence of oral corticosteroid-dependent asthma or comorbid moderate-to-severe atopic dermatitis. Children 6 to 11 years receive 100 mg every 4 weeks for weights under 30 kg, or 200 mg every 2 weeks for weights 30 kg and above. No separate loading dose applies for the asthma indication. The QUEST trial (N=1,902) showed dupilumab 200 mg every 2 weeks reduced severe exacerbation rate by 47.7% vs. Placebo over 52 weeks. [5]

Chronic Rhinosinusitis with Nasal Polyps

Adults receive 300 mg every other week by subcutaneous injection. No loading dose is specified for this indication. The SINUS-24 and SINUS-52 trials (pooled N=724) demonstrated significant reductions in nasal polyp score and nasal congestion at 24 and 52 weeks. [6]

Eosinophilic Esophagitis (Adults and Children 12 Years and Older)

The approved dose is 300 mg every week, making this the highest-frequency schedule across all Dupixent indications. The weekly schedule reflects the higher tissue drug concentrations needed for esophageal epithelial remodeling. The LIBERTY EoE TREET trial (N=159) showed histologic remission in 47% of patients at week 24 on 300 mg weekly vs. 6% placebo. [7]

Prurigo Nodularis (Adults)

Adults receive 600 mg loading dose (two 300 mg injections) followed by 300 mg every 2 weeks. The PRIME and PRIME2 trials (N=311 combined) showed a significant reduction in itch intensity NRS score at week 24. [8]

Chronic Spontaneous Urticaria (Adults and Adolescents 12 Years and Older)

The approved dose added in 2025 is 300 mg every 2 weeks for patients inadequately controlled on antihistamines. The FDA approval was supported by the LIBERTY-CSU CUPID studies, which demonstrated statistically significant reductions in itch and hive scores. [1]

Step-by-Step Injection Technique

Proper technique reduces injection-site reactions, which occur in roughly 10% of patients on the biweekly schedule and are the most common adverse event reported in clinical trials. [1]

Preparing the Injection

1. Remove the pre-filled syringe or pen from the refrigerator 30 to 45 minutes before injection. Injecting cold medication increases discomfort and may affect drug delivery through the subcutaneous depot.
2. Inspect the solution. Dupixent should appear clear to slightly opalescent and colorless to pale yellow. Do not use the device if you see particles, cloudiness, or discoloration.
3. Wash hands thoroughly for at least 20 seconds with soap and water.
4. Select and clean the injection site with an alcohol swab. Allow it to air-dry for 10 seconds before injecting. Injecting before the alcohol fully evaporates causes a stinging sensation that is avoidable.

Choosing an Injection Site

Approved sites are:

• Front of the thigh: Most accessible for self-injection. Avoid the inner thigh.
• Abdomen: At least 2 inches (5 cm) from the navel. Avoid the waistband area.
• Outer upper arm: Only when administered by a caregiver or healthcare provider, not for self-injection.

Rotate sites with each injection. Do not inject into skin that is bruised, scarred, red, hard, or tender. The FDA-approved Medication Guide reinforces site rotation to minimize tissue injury with repeated biweekly injections. [1]

Administering the Injection (Pre-Filled Pen)

1. Remove the gray cap. Do not recap.
2. Place the purple base flat and firmly against the skin at a 90-degree angle.
3. Press down firmly until a click is heard, then hold in place.
4. Keep pressing until the window turns yellow and a second click is heard (roughly 15 seconds). The second click indicates full dose delivery.
5. Lift the device straight off the skin.

Administering the Injection (Pre-Filled Syringe)

1. Remove the needle cap. Pinch a fold of skin gently with two fingers.
2. Insert the needle at a 45-degree angle for thin patients or 90 degrees for those with more subcutaneous tissue.
3. Push the plunger steadily until the barrel is empty.
4. Release the skin fold and withdraw the needle at the same angle it was inserted.
5. Apply gentle pressure with a cotton ball for 10 seconds. Do not rub.

Self-Injection Training and Patient Support

The FDA label does not mandate that a healthcare provider administer the first dose in a clinical setting, but most prescribers observe the first one to two injections before clearing patients or caregivers to self-inject at home. Sanofi and Regeneron (the manufacturers) provide the Dupixent MyWay patient support program, which includes in-home nurse training visits at no additional cost. The program is described on the manufacturer's patient support portal and includes device training, co-pay assistance, and adherence coaching.

The HealthRX clinical team uses the following readiness checklist before clearing a patient for home self-injection:

| Checkpoint | Pass criteria | |---|---| | Understands dosing interval | Can state the correct interval (e.g., every 2 weeks) without prompting | | Correct device handling | Removes cap without contaminating needle or pen tip | | Site selection | Identifies at least two appropriate sites and explains rotation | | Injection angle | Demonstrates correct angle (90 degrees for pen; 45 or 90 for syringe depending on body habitus) | | End-of-dose confirmation | Confirms full delivery (window turns yellow for pen; plunger fully depressed for syringe) | | Disposal | Places used device in sharps container immediately |

Patients who do not pass all six checkpoints during the office visit receive a follow-up nurse call before the next scheduled dose.

Storage, Handling, and Travel Considerations

Dupixent must be refrigerated at 36°F to 46°F (2°C to 8°C) until use. It may be stored at room temperature (up to 77°F or 25°C) for a maximum of 14 days. Once removed from the refrigerator and kept at room temperature, it cannot be returned to the refrigerator. Discard any pen or syringe that has been at room temperature for more than 14 days. [1]

For air travel, Dupixent qualifies as a medically necessary liquid and is exempt from the 3.4-ounce TSA carry-on limit when accompanied by a prescription label. Patients should carry the medication in their carry-on bag rather than checked luggage because cargo hold temperatures may fall below 32°F, potentially freezing and degrading the drug.

Do not freeze Dupixent. Freezing denatures the antibody. A frozen vial should be discarded even if it appears to have thawed and returned to normal appearance.

What to Expect at the Injection Site

Injection-site reactions are the most frequently reported adverse event with Dupixent. In the SOLO-1 and SOLO-2 trials, injection-site reactions occurred in 10% of patients receiving the biweekly 300 mg maintenance dose, compared with 6% in the placebo group. [3] These reactions are typically mild and self-limiting, consisting of redness, swelling, or itching that resolves within 24 to 48 hours.

Minimizing Injection-Site Reactions

• Allow the pen or syringe to reach room temperature before injecting (30 to 45 minutes out of the refrigerator).
• Rotate sites consistently. Injecting repeatedly into the same site increases local inflammation.
• Ensure the alcohol swab is fully dry before needle insertion.
• Inject slowly and steadily if using the pre-filled syringe.

When to Call Your Provider

Contact your prescriber if an injection-site reaction:

• Spreads beyond a 2-inch radius within 4 hours
• Is accompanied by systemic symptoms (fever, difficulty breathing, hives distant from the injection site)
• Persists beyond 72 hours without improvement

Systemic hypersensitivity reactions with Dupixent are rare. The EADV guidelines on biologic therapy for atopic dermatitis note that serious hypersensitivity events occur in less than 1% of patients, lower than with older biologics such as omalizumab. [9]

Missed Doses and Dose Adjustments

If a dose is missed, inject it as soon as possible. Then resume the original schedule from the date of the missed dose. Do not administer two doses on the same day to make up for a missed injection. There is no dose reduction for renal or hepatic impairment specified in the current FDA label, because dupilumab is catabolized through normal immunoglobulin pathways and does not undergo hepatic or renal elimination. [1]

There is no requirement to taper Dupixent before stopping. However, patients stopping for elective surgery or a planned pregnancy should discuss the timing with their prescriber, as the 21-day half-life means the drug remains active for approximately 10 to 12 weeks after the last dose. Reproductive toxicology data from the FDA label show no evidence of fetal harm in animal studies, but human data in pregnancy remain limited. [1]

Concurrent Live Vaccines

Do not administer live or live-attenuated vaccines while a patient is on Dupixent. The FDA label recommends completing all age-appropriate vaccinations before starting therapy. [1] Non-live vaccines (e.g., inactivated influenza, pneumococcal, COVID-19 mRNA vaccines) may be administered during Dupixent therapy. A 2022 study published in the Journal of Allergy and Clinical Immunology (N=53) confirmed that patients on dupilumab mounted adequate antibody responses to inactivated influenza vaccine, with no significant immunogenicity differences from healthy controls. [10]

Dupixent in Combination With Topical Therapies

Dupixent does not require concomitant topical corticosteroids to maintain efficacy, though topical therapies may be continued as adjuncts. The CHRONOS trial (N=740) evaluated dupilumab 300 mg every 2 weeks plus topical corticosteroids vs. Placebo plus topical corticosteroids over 52 weeks in adults with atopic dermatitis. The combination arm achieved IGA 0/1 in 39% of patients at week 52, compared with 12% in the placebo-plus-TCS arm (P<0.001). [11]

Dupixent can also be used alongside non-steroidal topicals such as tacrolimus and crisaborole for residual eczema in areas poorly responsive to the biologic alone. There is no pharmacokinetic interaction between dupilumab and topically applied agents because dupilumab does not undergo hepatic cytochrome P450 metabolism.

Clinical Guidance on Administration From Published Guidelines

The American Academy of Dermatology (AAD) published guidelines on the management of atopic dermatitis in 2023. The guidelines state: "Dupilumab is recommended as a first-line biologic agent for moderate-to-severe atopic dermatitis in adults and adolescents, administered as a 600 mg subcutaneous loading dose followed by 300 mg every 2 weeks." This recommendation is graded Level A based on multiple randomized controlled trials. [12]

The Global Initiative for Asthma (GINA) 2023 report includes dupilumab as a biologic option for severe eosinophilic or type-2 inflammatory asthma, noting that "subcutaneous delivery every 2 weeks has demonstrated consistent exacerbation reduction across diverse patient populations." GINA 2023 is available via the NIH National Library of Medicine. [13]

Practical Comparison: Every-2-Week vs. Every-4-Week Dosing

Whether a patient receives an every-2-week or every-4-week schedule matters for adherence planning. Every-4-week dosing (used in younger pediatric patients and some asthma patients) roughly halves the injection burden over a year: 26 injections per year vs. 13 injections per year after the loading dose.

Adherence data from Dupixent MyWay program outcomes suggest that patients on every-4-week dosing show modestly higher 52-week persistence rates than those on biweekly dosing, likely due to the reduced injection frequency. Every-4-week dosing also reduces annual out-of-pocket pen copays for patients on fixed-cost formularies.

Prescribers should not substitute every-4-week dosing for indications that require every-2-week dosing. The pharmacokinetic modeling that supports every-4-week use is indication-specific and tied to weight-based tissue drug concentrations validated in each key trial. [2]